Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etoposide + ifosfamide + mesna
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Etoposide + ifosfamide + mesna is a chemotherapy combination regimen used primarily for the treatment of soft tissue sarcomas, Ewing sarcoma/Ewing family of tumors, and testicular cancer. Etoposide is a topoisomerase II inhibitor that destroys quickly dividing cells. Ifosfamide is an alkylating agent that also targets rapidly dividing cells. Mesna is not a chemotherapeutic drug but serves as a uroprotective agent that prevents ifosfamide from irritating the bladder lining and causing hemorrhagic cystitis.
- Other names
- IESAIMEVIP
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on etoposide + ifosfamide + mesna.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etoposide + ifosfamide + mesna.